Antimicrobial susceptibility profile of Staphylococcus haemolyticus isolated from Vietnamese cancer patients over 4 years

S. haemolyticus is frequently colonizing the hospital environment and resistance to multiple antibiotics. The antimicrobial-resistant data of S. haemolyticus from Vietnamese cancer patients are limited. This study aims to evaluate the antimicrobial susceptibility profile of 41 S. haemolyticus isolated from Vietnamese cancer patients over a period of 4 years. The rate of methicillin-resistant and multidrug-resistant was 48.8% (20/41) and 95.1% (39/41), respectively. The most frequent sample was blood (65.9%, 27/41), and the second most frequent was sputum (12.2%, 5/41). All isolates were susceptible to quinupristin-dalfopristin, linezolid, tigecycline, and nitrofurantoin, and about 97% of isolates were susceptible to vancomycin. Approximately 96.88% of isolates were resistant to Benzylpenicillin and oxacillin, 93.75% were resistant to erythromycin, and 90.63% were resistant to Ciprofloxacin and Levofloxacin. The high level of methicillin and multidrug-resistant and reduced susceptibility to many antibiotics are causes of concern since they further narrow down the therapeutic options. Quinupristin-dalfopristin, linezolid, tigecycline, nitrofurantoin, and vancomycin are effective against S. haemolyticus infection in Vietnamese cancer patients at Vietnam National Cancer Hospital/Tan Trieu Base. Further studies are needed to surveillance bacterial resistance to guide antimicrobial therapy, reduce antimicrobial resistance rates, and improve the Vietnamese cancer patient’s care.